PatientsVille.com Logo

BLOOD GLUCOSE INCREASED and Pradaxa

PatientsVille

BLOOD GLUCOSE INCREASED Symptoms and Causes

We have all heard it many times before - regular exercise is good for you, and it can help you lose weight. But if you are like many Americans, you are busy, you have a sedentary job, and you haven't yet changed your exercise habits. The good news is that it's never too late to start. You can start slowly, and find ways to fit more physical activity into your life. To get the most benefit, you should try to get the recommended amount of exercise for your age. If you can do it, the payoff is that you will feel better, help prevent or control many diseases, and likely even live longer.

What are the health benefits of exercise?

Regular exercise and physical activity may

  • Help you control your weight. Along with diet, exercise plays an important role in controlling your weight and preventing obesity. To maintain your weight, the calories you eat and drink must equal the energy you burn. To lose weight, you must use more calories than you eat and drink.
  • Reduce your risk of heart diseases. Exercise strengthens your heart and improves your circulation. The increased blood flow raises the oxygen levels in your body. This helps lower your risk of heart diseases such as high cholesterol, coronary artery disease, and heart attack. Regular exercise can also lower your blood pressure and triglyceride levels.
  • Help your body manage blood sugar and insulin levels. Exercise can lower your blood sugar level and help your insulin work better. This can cut down your risk for metabolic syndrome and type 2 diabetes. And if you already have one of those diseases, exercise can help you to manage it.
  • Help you quit smoking. Exercise may make it easier to quit smoking by reducing your cravings and withdrawal symptoms. It can also help limit the weight you might gain when you stop smoking.
  • Improve your mental health and mood. During exercise, your body releases chemicals that can improve your mood and make you feel more relaxed. This can help you deal with stress and reduce your risk of depression.
  • Help keep your thinking, learning, and judgment skills sharp as you age. Exercise stimulates your body to release proteins and other chemicals that improve the structure and function of your brain.
  • Strengthen your bones and muscles. Regular exercise can help kids and teens build strong bones. Later in life, it can also slow the loss of bone density that comes with age. Doing muscle-strengthening activities can help you increase or maintain your muscle mass and strength.
  • Reduce your risk of some cancers, including colon, breast , uterine, and lung cancer.
  • Reduce your risk of falls. For older adults, research shows that doing balance and muscle-strengthening activities in addition to moderate-intensity aerobic activity can help reduce your risk of falling.
  • Improve your sleep. Exercise can help you to fall asleep faster and stay asleep longer.
  • Improve your sexual health. Regular exercise may lower the risk of erectile dysfunction (ED) in men. For those who already have ED, exercise may help improve their sexual function. In women, exercise may increase sexual arousal.
  • Increase your chances of living longer. Studies show that physical activity can reduce your risk of dying early from the leading causes of death, like heart disease and some cancers.
How can I make exercise a part of my regular routine?
  • Make everyday activities more active. Even small changes can help. You can take the stairs instead of the elevator. Walk down the hall to a coworker's office instead of sending an email. Wash the car yourself. Park further away from your destination.
  • Be active with friends and family. Having a workout partner may make you more likely to enjoy exercise. You can also plan social activities that involve exercise. You might also consider joining an exercise group or class, such as a dance class, hiking club, or volleyball team.
  • Keep track of your progress. Keeping a log of your activity or using a fitness tracker may help you set goals and stay motivated.
  • Make exercise more fun. Try listening to music or watching TV while you exercise. Also, mix things up a little bit - if you stick with just one type of exercise, you might get bored. Try doing a combination of activities.
  • Find activities that you can do even when the weather is bad.You can walk in a mall, climb stairs, or work out in a gym even if the weather stops you from exercising outside.

Check out the latest treatments for BLOOD GLUCOSE INCREASED

BLOOD GLUCOSE INCREASED treatment research studies

Pradaxa clinical trials, surveys and public health registries


Find Drug Side Effect reports



Pradaxa Side Effects

Gastrointestinal Haemorrhage (2049)
Anaemia (785)
Cerebrovascular Accident (760)
Haemorrhage (724)
Fall (618)
Rectal Haemorrhage (581)
Renal Failure Acute (471)
Dizziness (465)
Dyspepsia (439)
Haemorrhagic Anaemia (428)
Coagulopathy (420)
Dyspnoea (414)
Ischaemic Stroke (406)
Contusion (388)
Epistaxis (381)
Nausea (379)
Melaena (366)
Haemoglobin Decreased (363)
Asthenia (351)
Death (342)
Cerebral Haemorrhage (303)
Lower Gastrointestinal Haemorrhage (292)
Diarrhoea (283)
Haematuria (281)
Atrial Fibrillation (279)
Upper Gastrointestinal Haemorrhage (267)
Headache (267)
Pulmonary Embolism (264)
Haematochezia (264)
Deep Vein Thrombosis (258)
Myocardial Infarction (252)
Fatigue (246)
International Normalised Ratio Increased (241)
Haemorrhage Intracranial (239)
Renal Failure (235)
Arthralgia (230)
Transient Ischaemic Attack (218)
Abdominal Pain Upper (213)
Cerebral Infarction (207)
Chest Pain (207)
Abdominal Discomfort (198)
Pneumonia (192)
Vomiting (190)
Haematoma (181)
Abdominal Pain (178)
Subdural Haematoma (170)
Pain In Extremity (164)
Oedema Peripheral (164)
Renal Impairment (160)
Haemoptysis (156)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I'm over 80, very active working 6 days a week, walking briskly about 6 x 10 minutes daily, with Verapamil and 100 mg aspirin (also diabetic and asthmatic - completely under control). Had a biological aortic valve replacement, very s

While taking Pradaxa I had severe knife feeling pain in left eye. I have been off 2 days and it is better. I will check with eye docotr this week and see if it is eye or meds.

I have been Pradaxa for almost a month had severe outbreak of hives on my feet and my legs up to my knees. I also having swelling of legs and feet along with fatigue in joints and body limbs. Doctor changed my Med. but the side effects is still o

3 MONTHS TAKING PRADAXA WITH NO SIDE EFFECTS

Since taking Prodaxa I am experiencing shortness of breath...

I been taking pradaxa for 14 days and have a severe rash, doctor to start warfarin again.

my husband has been on pradaxa for a month he cannot eat has lost 26 lbs gets chills and then feels hot, vomiting.

Want to know if it could cause my extreme tiredness.

<b>Describe Your Pradaxa Experience Here:</b>tired and fluid retention

<b>Describe Your Pradaxa Experience Here:</b>itching that last five minutes and goes away i have swelled knee pain also arthritis

I've been taking Coversyl for almost two weeks now. My doctor prescribed it when the Natrilix I had been taking for a couple of months wasn't bringing my blood pressure down fast enough. The only side effects I've noticed since commencing the C

Does panadeine increase blood pressure?

I HAD 1 SHOT OF THIS AND WITHIN 12 HOURS I WENT FROM A VERY NORMAL BLOOD PRESSURE TO WAKING AT 5 A.M. NEXT DAY WITH 198/110 AND 104 PULSE RATE. IT HAS CONTINUED ALL WEEK AFTER AND I'M NOW ON A BLOOD PRESSURE DRUG TO TRY AND CONTROL IT. EVEN WITH DR

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

I have just come back from a funeral for my brother. He was just 62. He was on statin medicine but his cholestrol, blood pressure, weight and diet was very much in control. In fact just a day before his death the doctor told him that he was doing f

Side effects I have from Nadolol are confusion, dizziness, lightheaded, increased depression and anxiety, and mild nausea.

Since taking Karvezide (2years after Karvea was proved to unsuccessfull in reducing my high blood pressusre) I have experienced a lot of problems with nasal drip and a permanent muscas build up in the throat. Nothing seems to relieve the problem.

When I reported to my doctor that i was frequently having to urinate he had a blood test carried out with the result that my prostrate was OK he prescribed Permixon 160 mg twice per day and Tamsulosina STADA 0,4 mg once per day. I am now urinating

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

fell dizziness and was admitted. Doc execute with dianostic including blood teat and heart check all. good. Doc make a decision by saying i'm getting Vertigo and treat with BETASERC. Below is the effect after 2 days take this medicine:- I was

BLOOD GLUCOSE INCREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Management of Myocardial Injury After Noncardiac Surgery Trial
Condition: Myocardial Injury After Noncardiac Surgery (MINS)
Interventions: Drug: Dabigatran;   Drug: Placebo (for Dabigatran);   Drug: Omeprazole;   Drug: Placebo (for Omeprazole)
Outcome Measures: Major vascular complication (for Dabigatran);   Major upper gastrointestinal complication (for Omeprazole);   Individual secondary outcomes for Dabigatran;   Upper gastrointestinal complication for Omeprazole;   Major vascular complication for Omeprazole;   Individual secondary outcomes for Omeprazole;   Safety outcomes for Dabigatran;   Safety outcomes for Omeprazole
2 Recruiting Strategy of Continued Versus Interrupted Dabigatran at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
Condition: Hematoma
Intervention: Drug: Dabigatran
Outcome Measures: Clinically significant hematoma;   Composite of major peri-operative bleeding events and thrombo-embolic events
3 Recruiting Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively
Condition: Primary Disease
Interventions: Drug: Dabigatran;   Drug: Warfarin
Outcome Measures: Embolic Events;   Bleeding
4 Recruiting SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea
Condition: Atrial Fibrillation
Intervention: Drug: Pradaxa (Dabigatran etexilate mesilate)
Outcome Measures: Occurrence of adverse events;   Incidence rate of stroke;   Incidence rate of systemic embolism
5 Recruiting Drug Interaction Study Between Bosutinib And Dabigatran
Condition: Healthy
Interventions: Drug: Dabigatran;   Drug: Bosutinib
Outcome Measures: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Maximum Observed Plasma Concentration (Cmax);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Plasma Decay Half-Life (t1/2);   Apparent Oral Clearance (CL/F);   Apparent Volume of Distribution (Vz/F)
6 Recruiting Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation
Condition: Atrial Fibrillation
Intervention: Drug: Dabigatran etexilate (Pradaxa)
Outcome Measure: Percentage of fibrosis
7 Recruiting Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke
Conditions: Transient Ischemic Attack;   Minor Ischemic Stroke
Intervention: Drug: Dabigatran 110/150 mg BID
Outcome Measure: Symptomatic Hemorrhagic Transformation
8 Recruiting Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Conditions: Atrial Fibrillation;   Atrial Flutter
Intervention: Drug: dabigatran etexilate mesylate
Outcome Measures: Frequency of major bleeding complications and thrombo-embolic events in patients administered dabigatran following RF ablation.;   Dabigatran serum drug levels in patients experiencing a major bleeding or thrombo-embolic event.;   Frequency of minor bleeding events
9 Recruiting Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
Condition: Atrial Fibrillation
Intervention: Drug: Pradaxa, dabigatran etexilate
Outcome Measures: Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose;   Concentration of analyte in plasma at steady state at 2 hours after administration of the last dose
10 Recruiting Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
Condition: Venous Thromboembolism
Interventions: Drug: dabigatran etexilate;   Drug: standard of care
Outcome Measures: First component of the co-primary endpoint: A combined efficacy endpoint of complete thrombus resolution plus freedom from recurrent VTE plus freedom from mortality related to VTE;   Second component of the co-primary endpoint: Freedom from major bleeding events (a safety endpoint);   Pharmacokinetic assessments (plasma concentrations of total dabigatran) 3 days after start of treatment (after at least six consecutive dabigatran doses) and after 3 days following any dabigatran dose adjustment;   Frequency of dose adjustments;   Frequency of switch of type of anti-coagulation therapy (including dabigatran to SOC) and a switch from an intended standard of care treatment to another;   Freedom from thrombus progression at baseline and at days 21 and 84 after randomisation;   Assessment of the acceptability of an age-appropriate formulation at end of therapy;   Freedom from recurrence of VTE at 6, 9 and 12 months;   Freedom from occurrence of post-thrombotic syndrome at 6, 9 and 12 months;   All bleeding events;   All-cause mortality;   All components of the primary efficacy endpoints;   Pharmacodynamic assessments (aPTT, ecarin clotting time (ECT) and dTT) 3 days after start of treatment (after at least six consecutive dabigatran doses) and after 3 days following any dabigatran dose adjustment;   Frequency of temporary discontinuation from therapy;   Frequency of permanent discontinuation from therapy;   Number of laboratory monitoring requirements for dose adjustment during the treatment phase
11 Recruiting Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age
Condition: Venous Thromboembolism
Intervention: Drug: dabigatran etexilate
Outcome Measures: Plasma concentrations of total dabigatran;   Plasma concentrations of free dabigatran;   Plasma concentrations of BIBR 1048 BS (Base);   Plasma concentrations of BIBR 951 BS;   Plasma concentrations of BIBR 1087 SE (Acid);   Activated prothrombin time (aPTT);   Ecarin clotting time (ECT);   Factor IIa inhibition;   Incidence of all bleeding events;   Incidence of all adverse events;   Global assessment of tolerability will be summarized across all patients in the treated set;   Patient assessment of taste will be summarized across all patients in the treated set;   Changes in laboratory and clinical parameters
12 Recruiting Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
Conditions: Coronary Heart Disease;   Atrial Fibrillation;   Acute Coronary Syndrome;   Atherosclerosis
Interventions: Drug: Dabigatran;   Drug: Phenprocoumon
Outcome Measures: ADP induced platelet aggregation;   Platelet function tests;   Coagulation parameters
13 Not yet recruiting Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy
Condition: Venous Thrombembolic Events.
Intervention: Drug: Dabigatran.
Outcome Measure: Validation of a novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy
14 Not yet recruiting Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
Conditions: Atrial Fibrillation;   Hemorrhage
Interventions: Drug: Dabigatran 75 mg;   Drug: Dabigatran 150 mg
Outcome Measures: Number of patients with index event safety outcomes (ongoing/resolved/deceased);   Number of patients receiving different types of interventions to stop the index events;   Frequencies of bleeding types and anatomic locations of the index event
15 Recruiting Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age
Condition: Venous Thromboembolism
Intervention: Drug: dabigatran etexilate
Outcome Measures: Ecarin clotting time (ECT);   Factor IIa inhibition;   Incidence of all bleeding events;   Incidence of all adverse events;   Plasma concentrations of total dabigatran;   Plasma concentrations of free dabigatran;   Plasma concentrations of BIBR 1048 BS (Base);   Plasma concentrations of BIBR 951 BS;   Plasma concentrations of BIBR 1087 SE (Acid);   Activated prothrombin time (aPTT);   Global assessment of tolerability will be summarized across all patients in the treated set;   Patient assessment of taste will be summarized across all patients in the treated set;   Changes in laboratory and clinical parameters
16 Recruiting Safety Study of Dabigatran in CADASIL
Condition: CADASIL
Interventions: Drug: Dabigatran;   Drug: Antiplatelets
Outcome Measures: Number of microbleeds on MRI;   Major bleeding
17 Not yet recruiting Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
Condition: Atrial Fibrillation
Interventions: Drug: Warfarin;   Drug: Dabigatran
Outcome Measures: Cognitive impairment;   Number of Participants with less important alteration in coagulation test as a Measure of Safety
18 Recruiting Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Condition: Hemorrhage
Intervention: Drug: idarucizumab
Outcome Measures: Reversal of anticoagulant effect of dabigatran;   Reversal of Activated Partial Thromboplastin Time (aPTT);   Reversal of Thrombin Time (TT);   Duration of reversal;   Occurrence of major bleeding post-surgery (for Group B only);   Time to cessation of bleeding (for Group A only);   Minimum unbound sum (free) dabigatran;   Reversal of diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) after the first infusion and before the start of the second
19 Recruiting Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
Condition: Healthy Volunteers
Interventions: Drug: D->R->C+R;   Drug: D->R->C+D;   Drug: R->D->C+D;   Drug: R->D->C+R
Outcome Measures: AUC of plasma concentrations of the drugs;   PKD of the drugs
20 Recruiting Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
Conditions: Arthroplasty, Replacement;   Thromboembolism
Intervention:
Outcome Measures: Safety: Major bleeding events. Efficacy: composite of all death and documented symptomatic VTE (i.e documented symptomatic DVT and documented symptomatic nonfatal pulmonary embolism).;   Major extra surgical site bleedings,volume of wound drainage, documented symptomatic proximal DVT, documented symptomatic distal DVT, documented symptomatic nonfatal pulmonary embolism and all-cause mortality